Eurofins Scientific SE ERF

LUXEMBOURG, October 02, 2026--Regulatory News: Eurofins Scientific (EUFI.PA) (Paris:ERF), a global scientific leader in bioanalytical testing, announces the successful closing of its acquisition of the Life Sciences Testing Services business in North America of Element Materials Technology ("Element"), which took place on 1 October 2026. The transaction was announced on 20 July 2026 for an enterprise value of USD400m.

LUXEMBOURG, October 02, 2026--Regulatory News: Eurofins Scientific SE (Paris:ERF) (the "Company" or "Eurofins") (EUFI.PA) announces the completion of the divestment of its Electrical & Electronic Testing business ("MET Labs") to UL Solutions Inc., which took place on 1 October 2026. The transaction was announced on 14 April 2026 for an Enterprise Value of €575 million on a cash and debt free basis.

NORTHBROOK, Ill., October 01, 2026--UL Solutions Inc. (NYSE: ULS), a global leader in applied safety science, today announced it has completed the acquisition of the electrical and electronics (E&E) business of Eurofins Scientific SE.

Eurofins Scientific has delivered a 48.5% gain over the past three years, which puts fresh focus on whether that move is fully supported by the cash it is expected to generate. With the stock recently closing at €75.00, the key issue for you is how that price lines up with the intrinsic value suggested by its cash flows. The 48.5% return over three years puts existing holders in a comfortable position on paper. It also raises the question of whether the underlying cash flow profile has kept...

Eurofins Scientific (ENXTPA:ERF) has been highlighted as a major competitor in a new global Central Labs market report running through 2032. The study links sector expansion to AI driven analytics, precision medicine programs and greater outsourcing of clinical trial lab work. Eurofins is cited among leading providers as decentralized and hybrid clinical trial models increase demand for coordinated global lab services. The spotlight on Eurofins in this long term Central Labs growth report...

Central labs benefit from trial outsourcing, precision medicine, biomarker research, AI and automation, decentralized trials, and expanding clinical activity in emerging markets.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Central Labs - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global Central Labs market, estimated at US$3.0 billion in 2025, is projected to reach US$4.4 billion by 2032, expanding at a compound annual growth rate (CAGR) of 5.8%. Ma

LUXEMBOURG, September 29, 2026--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below.

LUXEMBOURG, September 28, 2026--Regulatory News: Eurofins Scientific SE (Paris:ERF):

LUXEMBOURG, September 21, 2026--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below.

LUXEMBOURG, September 21, 2026--Regulatory News: Eurofins (Paris:ERF):

LUXEMBOURG, September 16, 2026--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below.

LUXEMBOURG, September 14, 2026--Regulatory News: Eurofins Scientific SE (Paris:ERF):